SCOPE FLUIDICS S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 178.4 PLN | -3.98% |
|
-5.21% | -8.98% |
| Sales 2021 | - | Sales 2022 | 404K 99.92K | Capitalization | 566M 140M |
|---|---|---|---|---|---|
| Net income 2021 | -16M -3.96M | Net income 2022 | 318M 78.65M | EV / Sales 2021 | - |
| Net cash position 2021 | 4.62M 1.14M | Net cash position 2022 | 329M 81.4M | EV / Sales 2022 | 585 x |
| P/E ratio 2021 |
-22
x | P/E ratio 2022 |
1.75
x | Employees | 30 |
| Yield 2021 * |
-
| Yield 2022 |
41.2% | Free-Float | 73.44% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.23% | ||
| 1 week | -4.46% | ||
| Current month | -10.99% | ||
| 1 month | -10.55% | ||
| 3 months | -20.09% | ||
| 6 months | +10.65% | ||
| Current year | -8.27% |
1 week
178.00
191.00
1 month
178.00203.00
Current year
178.00239.00
1 year
148.00239.00
3 years
83.00348.00
5 years
32.40348.00
10 years
9.55348.00
| Managers | Title | Age | Since |
|---|---|---|---|
Piotr Garstecki
CEO | Chief Executive Officer | 48 | 09-12-31 |
Marcin Izydorzak
FOU | Founder | 50 | 09-12-31 |
Szymon Ruta
DFI | Director of Finance/CFO | 48 | 16-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 49 | 17-03-06 | |
| Director/Board Member | 48 | 17-03-06 | |
| Founder | 61 | 09-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 178.4 | -3.98% | 5 089 |
| 24-04-18 | 185.8 | 0.00% | 642 |
| 24-04-17 | 185.8 | -1.38% | 1,685 |
| 24-04-16 | 188.4 | -1.15% | 981 |
| 24-04-15 | 190.6 | +1.28% | 669 |
Delayed Quote Warsaw S.E., April 19, 2024 at 10:01 am EDT
More quotes
Scope Fluidics SA is a Poland-based company engaged in the biotechnology. The Company focuses on diagnostic and med-tech solutions. It develops disposable microfluidic systems for the collection of micro-samples of blood, as well as storage of reagents for diagnostic markers. Its projects include PCR ONE system that delivers the bacterial and viral pathogen detection, and BacterOMIC system that delivers information on bacterial susceptibility to antibiotics and on the resistance mechanisms. The Company provides access to laboratories and workshops for developed projects, as well as administrative facilities and services, including financing. In addition, it cooperates with doctors, medical personnel, project managers, engineers and academics.
| 1st Jan change | Capi. | |
|---|---|---|
| -8.27% | 125M | |
| -15.41% | 11.52B | |
| +43.11% | 3.27B | |
| -19.90% | 2.02B | |
| -29.59% | 1.44B | |
| +15.57% | 1.01B | |
| -6.11% | 719M | |
| -31.50% | 418M | |
| -51.12% | 339M | |
| -3.18% | 284M |
- Stock Market
- Equities
- SCP Stock
